## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.6% below STRENGTH zone (3.0-6.0%); PEG 35.34 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Baxter International Finalizes Tender Offers Settlement**
- Source: TradingView â€” Track All Markets | 20251222T220753 | Neutral | Relevance: 100%
- Baxter International (BAX) has finalized the settlement of its cash tender offers for 2026 and 2027 Notes, which had expired on December 18, 2025. The company accepted $2,610,000 of 2026 Notes after the early tender date, with late tender notes priced at $960.50 per $1,000. This concludes the previously announced tender offer process.

**2. Baxter International Completes Cash Tender Offers, Cuts Debt**
- Source: TipRanks | 20251222T222153 | Somewhat-Bearish | Relevance: 97%
- Baxter International has successfully completed cash tender offers for its 2026 and 2027 senior unsecured notes, significantly reducing its near-term debt obligations. The company purchased over $420 million of 2026 notes and more than $614 million of 2027 notes, effectively discharging the former and fully subscribing the latter offer. While BAX stock has a "Hold" rating from analysts, TipRanks' AI Analyst Spark views it as Neutral due to financial and operational challenges despite some positive developments.

**3. Baxter International completes final settlement of tender offers for senior notes**
- Source: Investing.com | 20251222T224053 | Neutral | Relevance: 97%
- Baxter International Inc. completed the final settlement of its cash tender offers for outstanding senior unsecured notes due in 2026 and 2027. The company purchased all outstanding 2026 notes and the fully subscribed 2027 notes, effectively settling these obligations. This move comes amid other recent company developments including improvements in patient safety through technology integration, a Moody's credit downgrade due to debt concerns, and a voluntary hold on certain infusion pumps.

**4. Churchill Downs, Incorporated $CHDN Shares Purchased by Secure Asset Management LLC**
- Source: MarketBeat | 20251220T120904 | Somewhat-Bullish | Relevance: 64%
- Secure Asset Management LLC significantly increased its stake in Churchill Downs (NASDAQ:CHDN) by 63% in Q3, now owning 37,764 shares valued at $3.65 million. This reflects a broader institutional confidence, with several other large funds also boosting their positions in the company, which recently beat Q3 earnings and revenue estimates. Churchill Downs also increased its annual dividend to $0.438 per share, maintaining a "Buy" consensus analyst rating.

**5. UBS Reiterates Buy Rating on Boston Scientific (BSX)**
- Source: Finviz | 20251221T094400 | Neutral | Relevance: 60%
- UBS has reiterated its "Buy" rating on Boston Scientific (BSX) with a $140 price target, despite a recent share drop. Analyst Danielle Antalffy believes the risk/reward profile is skewed to the upside, citing expectations for sustained momentum in high-growth areas and the CEO's commitment to grow divisions like Electrophysiology and the WATCHMAN device above market rates. UBS anticipates 2026 sales growth to exceed Boston Scientific's long-range target of 10-12%, primarily driven by the WATCHMAN business.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.17M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.3x requires aggressive growth execution.
2. Elevated short interest (9.7%): bears positioning against stock.
3. Long-term trend broken: trading 27.3% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 35.34 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.8B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.34 |
| Forward P/E | 8.2 |
| Current P/E | 8.0 |
| YoY Growth | -2.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.2% to -0.6% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.6pp (needs >3.0% for momentum thesis). Below SMA200 (0.73x), long-term trend not supportive. RSI neutral at 49. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.60% (CS: 40) | Neutral |
| RSI_14 | 49.3 | Neutral |
| MACD Histogram | 0.13 | Bullish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 0.966x | Below |
| vs SMA200 | 0.727x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.96
- **Stop Loss:** $17.90 (5.6% risk)
- **Target:** $20.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1132
- **Position Value:** $21,462.72
- **Portfolio %:** 21.46%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*